Table 2.
Correlation of BRAF status and clinicopathological characteristics.
| BRAF status | ||
|---|---|---|
| BRAF wild-type | BRAF-mutated | |
| Cytology diagnosis: | ||
| Thy 3 | 34/38 (90%) | 6/38 (16%) |
| Thy 4 | 10/18 (56%) | 8/18 (44%) |
| Final histology: | ||
| FTC | 5/42 (12%) | 0/14 (0%) |
| PTC | 2/42 (5%) | 11/14 (79%) |
| Nodular hyperplasia colloid or follicular adenoma | 28/42 (67%) | 2/14 (14%) |
| mPTC | 3/42 (7%) | 0/14 (0%) |
| Combined cell carcinoma and PTC | 1/42 (2.25%) | 0/14 (0%) |
| MTC | 1/42 (2.25%) | 0/14 (0%) |
| Hurtle neoplasia | 1/42 (2.25%) | 0/14 (0%) |
| fPTC | 1/42 (2.25%) | 1/14 (7%) |
PTC = papillary thyroid carcinoma; FTC = follicular thyroid carcinoma; MTC = medullary thyroid carcinoma; fPTC = follicular variant of papillary carcinoma; mPTC = papillary microcarcinoma.